TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31245160
Drug: Intraoperative endoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative endoscopic submucosal injection of dual tracer (radioisotope and indocyanine green) with sentinel basins detected using gamma-probe
Study: 31245160
Drug: Endoscopic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic injection of indocyanine green (ICG) with sentinel basins detected using a fluorescence imaging system
Study: 31247117
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg adefovir-dipivoxil (OAT1)
Study: 31250322
Drug: Brivaracetam oral
Normalized name: brivaracetam Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivaracetam oral solution (dosage increased weekly: 0.8, 1.6, 3.2 mg/kg/day for patients ≥ 8 years; 1.0, 2.0, 4.0 mg/kg/day for patients < 8 years)
Study: 31250322
Drug: Brivaracetam oral
Normalized name: brivaracetam Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivaracetam oral solution
Study: 31250445
Drug: Antidepressant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant treatment (selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, or vortioxetine) for 8 weeks
Study: 31250829
Drug: Feminizing hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Feminizing hormone therapy and adherence counseling; Peer health navigation
Study: 31251543
Drug: 0.3% A/BPO
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% A/BPO treatment
Study: 31253572
Drug: IPH4102 (monoclonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPH4102 (monoclonal antibody targeting KIR3DL2) administered as an intravenous infusion at a flat dose of 750 mg during cohort-expansion.
Study: 31253596
Drug: AMG 232
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 232 monotherapy (arm 1) at doses of 60, 120, 240, 360, 480, or 960 mg
Study: 31253596
Drug: AMG 232
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 232 at 60 mg with trametinib 2 mg (arm 2)
Study: 31253596
Drug: Common treatment-related
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common treatment-related AEs for AMG 232
Study: 31253596
Drug: Pharmacokinetics of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacokinetics of AMG 232
Study: 31253727
Drug: Peg-IFN-α2a monotherapy
Normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peg-IFN-α2a monotherapy after 12 weeks
Study: 31253727
Drug: Peg-IFN-α2a immunotherapy
Normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peg-IFN-α2a immunotherapy
Study: 31253732
Drug: Self-reported questionnaires
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported questionnaires including the Hospital Anxiety and Depression Scale, the Functional Assessment of Cancer Therapy (FACT), General and Brain (FACT-Br), and the Leisure Time Physical Activity Questionnaire.
Study: 31254273
Drug: Plazomicin-based combination
Normalized name: plazomicin
DrugBank: Plazomicin (DB12615)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plazomicin-based combination therapy (with adjunctive tigecycline or meropenem)
Study: 31254273
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Colistin-based combination therapy)
Study: 31254392
Drug: Glecaprevir/Pibrentasvir (G/P)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glecaprevir/Pibrentasvir (G/P) 300 mg/120 mg once daily for 8-16 weeks
Study: 31254392
Drug: Glecaprevir/Pibrentasvir (G/P)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glecaprevir/Pibrentasvir (G/P)
Study: 31255290
Drug: Closed-loop vasopressor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop vasopressor (CLV) control with norepinephrine infusion
Study: 31256026
Drug: Secure prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secure prescription pads for zolpidem
Study: 31256030
Drug: Multimodal imaging
Normalized name: triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multimodal imaging and image review by an ophthalmic grader
Study: 31256774
Drug: Post-operative multimodal
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operative multimodal analgesic regimen
Study: 31257724
Drug: Obinutuzumab (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obinutuzumab (1000 mg) plus IVIG
Study: 31259266
Drug: No anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anticoagulant
Study: 31260835
Drug: GSK2879552 (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2879552 (0.25 mg-3 mg once daily and 3-mg or 4-mg intermittent dosing)
Study: 31261514
Drug: Apatinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib plus docetaxel (docetaxel 75 mg/m² i.v. on day 1 plus oral apatinib 250 mg/day)
Study: 31262585
Drug: Hecolin® vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hecolin® vaccine (3 doses at day 0, month 1, month 6)
Study: 31262783
Drug: CD19-specific chimeric
Normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD19-specific chimeric antigen receptor (CAR) T cells administered following high-dose chemotherapy and autologous stem cell transplantation (HDT-ASCT) on days +2 and +3.
Study: 31263960
Drug: Daily physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily physical activity assessed in steps/day using an arm-worn accelerometer (SenseWear) over 1 week.
Study: 31263960
Drug: 6-minute walking
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-minute walking distance (6MWD) as an independent predictor of daily steps.
Study: 31263960
Drug: Correlation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation of daily physical activity with hemodynamics and other outcomes.
Study: 31267239
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of beta-blockers, renin-angiotensin system inhibitors, and mineralocorticoid receptor antagonists
Study: 31267365
Drug: Strength training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength training exercises in more simple forms (e.g. elastic bands, body weight)
Study: 31267801
Drug: Adalimumab with
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab with ≥12 mg/week methotrexate
Study: 31269208
Drug: Raltegravir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir (400 mg twice daily) / Etravirine (200 mg twice daily)
Study: 31270103
Drug: DARA-MD 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: DARA-MD 1200 mg
Study: 31270103
Drug: DARA-MD 1800
Approvals — FDA: no, EMA: no, PMDA: no
Description: DARA-MD 1800 mg
Study: 31271463
Drug: Maternal tenofovir
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Maternal tenofovir treatment during the third trimester
Study: 31271463
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no tenofovir treatment)
Study: 31273088
Drug: Eltrombopag, an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag, an oral thrombopoietin-mimetic, dosage and duration not specified
Study: 31274114
Drug: Biological markers
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological markers for drug use
Study: 31274114
Drug: Biological markers
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological markers for sexual HIV transmission risk
Study: 31274114
Drug: Biological markers
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological markers for PrEP adherence
Study: 31276005
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment for ATR
Study: 31276163
Drug: Nivolumab (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (240 mg) IV every 2 weeks
Study: 31277699
Drug: MK-2206 (AKT
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-2206 (AKT inhibitor)
Study: 31277722
Drug: Sedatives only
Normalized name: Sed-Max
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedatives only
Study: 31277722
Drug: Sedatives plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedatives plus opioids
Study: 31279304
Drug: Ibrutinib (560
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib (560 mg/day) until disease progression or unacceptable toxicity
Study: 31279304
Drug: Ibrutinib (560
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib (560 mg/day)
Study: 31279564
Drug: MenACWY-CRM (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY-CRM (4 doses during infancy)
Study: 31279564
Drug: MenACWY-CRM (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY-CRM (2 doses at 12/13 and 15 months or 1 dose at 18 months)
Study: 31279564
Drug: MenACWY-CRM booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY-CRM booster dose at 60 months
Study: 31279871
Drug: Vedolizumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vedolizumab (300 mg intravenously at weeks 0, 2, and 6, then every 8 weeks thereafter for 26 weeks)
Study: 31280362
Drug: Erdafitinib (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erdafitinib (doses ranging from 0.5 to 12 mg, with a highest therapeutic dose of 9 mg daily)
Study: 31284072
Drug: Patent Blue
Normalized name: Patent Blue
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patent Blue injection into different parts of the pancreas
Study: 31284680
Drug: Aerosol with
Normalized name: AEROSOL WITH ADAPTER (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosol with active heated humidification at 10 L/min
Study: 31284680
Drug: Aerosol with
Normalized name: AEROSOL WITH ADAPTER (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosol with active heated humidification at 30 L/min
Study: 31284680
Drug: Aerosol with
Normalized name: AEROSOL WITH ADAPTER (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosol with active heated humidification at 50 L/min
Study: 31284680
Drug: Aerosol with
Normalized name: AEROSOL WITH ADAPTER (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosol with unheated oxygen at 10 L/min
Study: 31284680
Drug: Aerosol with
Normalized name: AEROSOL WITH ADAPTER (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosol with unheated oxygen at 30 L/min
Study: 31284680
Drug: Aerosol with
Normalized name: AEROSOL WITH ADAPTER (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosol with unheated oxygen at 50 L/min
Study: 31285871
Drug: Hyperthermic intrapleural
Normalized name: INTRAPLEURAL MEDICATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperthermic intrapleural chemotherapy (HITHOC)
Study: 31286197
Drug: Infrapopliteal drug-coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infrapopliteal drug-coated balloon angioplasty with the ELUTAX SV DCB
Study: 31288365
Drug: Intravenous indocyanine
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous indocyanine green (5 mg/kg) 24 hours before metastasectomy
Study: 31289029
Drug: Autologous T
Normalized name: DNP-Modified autologous tumor vaccine
DrugBank: DNP-Modified autologous tumor vaccine (DB17436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous T cells engineered to express an affinity-enhanced T-cell receptor (TCR) recognizing NY-ESO-1 and LAGE-1
Study: 31289090
Drug: Early parenteral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early parenteral nutrition (PN) during the first 7 postnatal days
Study: 31290084
Drug: Multimodal analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal analgesia protocol (paracetamol, oxycodone, methoxyflurane)
Study: 31291010
Drug: HPV vaccine
Normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV vaccine intent
Study: 31291010
Drug: Provider recommendation
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provider recommendation for the HPV vaccine
Study: 31291010
Drug: Positive general
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive general attitude toward vaccines
Study: 31291010
Drug: Vaccine intent
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine intent
Study: 31291057
Drug: Early antiretroviral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early antiretroviral therapy (E-ART); provided to 105 FSWs; retention at end of study: 59.0% (62/105); mean duration of follow-up: 13.4 (±7.9) months; self-reported adherence over 90%.
Study: 31291801
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clinical and device diagnostic parameters.
Study: 31291985
Drug: Selinexor combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selinexor combined with high-dose cytarabine (HiDAC) and mitoxantrone (Mito)
Study: 31292901
Drug: Trimetazidine (TMZ)
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (TMZ) treatment for 14 days
Study: 31294762
Drug: Pembrolizumab therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab therapy (200 mg every 21 days for 8 cycles, with provision to continue to 16 cycles)
Study: 31294762
Drug: Pembrolizumab therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab therapy
Study: 31296225
Drug: TyG index
Normalized name: Tygacil
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TyG index (calculated using Ln(fasting triglycerides (mg/dl) × fasting blood glucose (mg/dl)/2))
Study: 31296423
Drug: Lenalidomide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide (20 mg) plus obinutuzumab (1000 mg) as induction therapy for six 28-day cycles.
Study: 31296423
Drug: Lenalidomide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide (10 mg) plus obinutuzumab (1000 mg) for 1-year maintenance (12 28-day cycles; days 2-22) and obinutuzumab (1000 mg) for 1-year maintenance (six 56-day cycles; day 1).
Study: 31296423
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy with lenalidomide plus obinutuzumab.
Study: 31296923
Drug: Post-operative CEA
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operative CEA ≤ 2.35 ng/mL
Study: 31296923
Drug: Post-operative CEA
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operative CEA > 2.35 ng/mL
Study: 31296923
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of oxaliplatin to adjuvant treatment
Study: 31297046
Drug: Hypnotic Suggestion
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic Suggestion
Study: 31297636
Drug: PF-04136309 (CCR2
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-04136309 (CCR2 inhibitor) plus nab-paclitaxel (125 mg/m2) and gemcitabine
Study: 31297647
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy (HT) with aromatase inhibitors
Study: 31298497
Drug: Feminizing hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Feminizing hormone therapy (E2 valerate and cyproterone acetate) prescribed at baseline until week 5, and then from week 8 until the end of study.
Study: 31298497
Drug: Daily pre-exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate/emtricitabine initiated at week 3 and continued without interruption.
Study: 31299005
Drug: M6620 (ATR
Approvals — FDA: no, EMA: no, PMDA: no
Description: M6620 (ATR inhibitor) and cisplatin
Study: 31299007
Drug: Serial measurement
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serial measurement of optic nerve sheath diameter (ONSD) during therapy for DKA.
Study: 31299074
Drug: efavirenz-based ART
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: efavirenz-based ART (600 mg daily)
Study: 31299074
Drug: nevirapine-based ART
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nevirapine-based ART (200 mg twice daily)
Study: 31299650
Drug: Clazosentan administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clazosentan administration
Study: 31299972
Drug: Chronic kidney
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic kidney disease (CKD) diagnosed with eGFR < 60 mL/min/1.73m²
Study: 31300344
Drug: MGN1703 (TLR9
Approvals — FDA: no, EMA: no, PMDA: no
Description: MGN1703 (TLR9 agonist) for 24 weeks
Study: 31301962
Drug: Ramucirumab 8
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ramucirumab 8 mg/kg + Pembrolizumab 200 mg
Study: 31301962
Drug: Ramucirumab 10
Normalized name: ramucirumab 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramucirumab 10 mg/kg + Pembrolizumab 200 mg
Study: 31302344
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy (CTx) with TS-1 (35 mg/m²) for two 21-day courses followed by chemoradiotherapy (CCRT)
Study: 31303280
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement containing salmon's milt extract, 1 capsule per day for the first 4 weeks, then 1 capsule in the morning and 1 capsule in the evening for the remaining 8 weeks
Study: 31303280
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement containing salmon's milt extract
Study: 31303643
Drug: CFI-400945 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CFI-400945 at 64 mg/day
Study: 31303643
Drug: CFI-400945 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CFI-400945 at 96 mg/day
Study: 31303643
Drug: CFI-400945 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CFI-400945 at 72 mg/day
Study: 31303643
Drug: CFI-400945 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CFI-400945 at 3 to 96 mg/day
Study: 31306555
Drug: Daprodustat 4
Normalized name: daprodustat 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daprodustat 4 mg once daily for 4 weeks, with dose adjustments thereafter
Study: 31306621
Drug: OAC ±
Normalized name: Oral Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC ± AP therapy
Study: 31306621
Drug: AP therapy
Normalized name: AP-101
DrugBank: AP-101 (DB17947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AP therapy
Study: 31306621
Drug: Dual AP
Normalized name: AP-101
DrugBank: AP-101 (DB17947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual AP therapy
Study: 31306621
Drug: OAC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC with or without AP therapy
Study: 31307216
Drug: Maternal DENV
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal DENV neutralizing antibodies
Study: 31307216
Drug: DENV-4 neutralizing
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: DENV-4 neutralizing antibody
Study: 31307482
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D deficient (<50 nmol/L)
Study: 31307482
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D insufficient (50-75 nmol/L)
Study: 31307482
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D replete (>75 nmol/L)
Study: 31309541
Drug: Oral CHOP-like
Normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral CHOP-like chemotherapy
Study: 31310310
Drug: rhPTH(1-84) therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhPTH(1-84) therapy for 8 years
Study: 31311898
Drug: Polypharmacy (defined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypharmacy (defined as the use of 5 or more medications at one time)
Study: 31311898
Drug: Drug-drug interactions
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-drug interactions (DDIs) determined using the Lexicomp Online drug interaction screening tool
Study: 31311898
Drug: Potentially inappropriate
Normalized name: Potentilla discolor whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potentially inappropriate medications defined based on the 2015 update of the Beers Criteria
Study: 31312030
Drug: Binimetinib and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Binimetinib and capecitabine (DL3 dose level)
Study: 31312030
Drug: Binimetinib and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Binimetinib and capecitabine (DL3 dose level) in patients with RAS/RAF/MEK/ERK pathway mutations
Study: 31312536
Drug: Nivolumab monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab monotherapy (NIVO)
Study: 31312536
Drug: Ipilimumab monotherapy
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab monotherapy (IPI)
Study: 31316378
Drug: Four off-label
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four off-label metabolically targeted medicines
Study: 31316785
Drug: Single-dose fecal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose fecal microbiota transplant (FMT)